@article{1f6b0fdc6cf8418e8e11af7cb858da34,
title = "Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors",
abstract = "Background & Aims: Guidelines for initiating colorectal cancer (CRC) screening are based on family history but do not consider lifestyle, environmental, or genetic risk factors. We developed models to determine risk of CRC, based on lifestyle and environmental factors and genetic variants, and to identify an optimal age to begin screening. Methods: We collected data from 9748 CRC cases and 10,590 controls in the Genetics and Epidemiology of Colorectal Cancer Consortium and the Colorectal Transdisciplinary study, from 1992 through 2005. Half of the participants were used to develop the risk determination model and the other half were used to evaluate the discriminatory accuracy (validation set). Models of CRC risk were created based on family history, 19 lifestyle and environmental factors (E-score), and 63 CRC-associated single-nucleotide polymorphisms identified in genome-wide association studies (G-score). We evaluated the discriminatory accuracy of the models by calculating area under the receiver operating characteristic curve values, adjusting for study, age, and endoscopy history for the validation set. We used the models to project the 10-year absolute risk of CRC for a given risk profile and recommend ages to begin screening in comparison to CRC risk for an average individual at 50 years of age, using external population incidence rates for non-Hispanic whites from the Surveillance, Epidemiology, and End Results program registry. Results: In our models, E-score and G-score each determined risk of CRC with greater accuracy than family history. A model that combined both scores and family history estimated CRC risk with an area under the receiver operating characteristic curve value of 0.63 (95% confidence interval, 0.62–0.64) for men and 0.62 (95% confidence interval, 0.61–0.63) for women; area under the receiver operating characteristic curve values based on only family history ranged from 0.53 to 0.54 and those based only E-score or G-score ranged from 0.59 to 0.60. Although screening is recommended to begin at age 50 years for individuals with no family history of CRC, starting ages calculated based on combined E-score and G-score differed by 12 years for men and 14 for women, for individuals with the highest vs the lowest 10% of risk. Conclusions: We used data from 2 large international consortia to develop CRC risk calculation models that included genetic and environmental factors along with family history. These determine risk of CRC and starting ages for screening with greater accuracy than the family history only model, which is based on the current screening guideline. These scoring systems might serve as a first step toward developing individualized CRC prevention strategies.",
keywords = "Colon Cancer, Colonoscopy, CORECT, GECCO",
author = "{Colorectal Transdisciplinary Study and Genetics and Epidemiology of Colorectal Cancer Consortium} and Jihyoun Jeon and Mengmeng Du and Schoen, {Robert E.} and Michael Hoffmeister and Newcomb, {Polly A.} and Berndt, {Sonja I.} and Bette Caan and Campbell, {Peter T.} and Chan, {Andrew T.} and Jenny Chang-Claude and Giles, {Graham G.} and Jian Gong and Harrison, {Tabitha A.} and Huyghe, {Jeroen R.} and Jacobs, {Eric J.} and Li Li and Yi Lin and {Le Marchand}, Lo{\"i}c and Potter, {John D.} and Conghui Qu and Bien, {Stephanie A.} and Niha Zubair and Macinnis, {Robert J.} and Buchanan, {Daniel D.} and Hopper, {John L.} and Yin Cao and Reiko Nishihara and Gad Rennert and Slattery, {Martha L.} and Thomas, {Duncan C.} and Woods, {Michael O.} and Prentice, {Ross L.} and Gruber, {Stephen B.} and Yingye Zheng and Hermann Brenner and Hayes, {Richard B.} and Emily White and Ulrike Peters and Li Hsu",
note = "Funding Information: The authors would like to express their deepest thanks to the families and patients who have so generously provided their time and biological samples to the Newfoundland Colorectal Cancer Registry (NFCCR). Supported by the Canadian Institutes of Health Research grant CRT-43821; and the genotyping of the samples was conducted by Dr Stephen B Gruber, USC Norris Comprehensive Cancer Center, University of Southern California as part of the ColoRectal Transdisciplinary Study (CORECT). Funding Information: Funding This work was supported by grants as follows: Hawaii Colorectal Cancer Studies 2 and 3 are supported by National Institutes of Health (R01 CA60987). The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II cohort. Darmkrebs: Chancen der Verh{\"u}tung durch Screening: German Research Council is supported by Deutsche Forschungsgemeinschaft (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4 and CH 117/1-1), and the German Federal Ministry of Education and Research (01KH0404 and 01ER0814). Diet, Activity and Lifestyle Study is supported by National Institutes of Health (R01 CA48998 to M. L. Slattery). Nurses{\textquoteright} Health Study and Health Professionals Follow-up Study: Health Professionals Follow-up Study is supported by the National Institutes of Health (P01 CA055075, UM1 CA167552, R01 CA137178, R01 CA151993, R35 CA197735, K07 CA190673, and P50 CA127003), Nurses{\textquoteright} Health Study is supported by the National Institutes of Health (R01 CA137178, P01 CA087969, UM1 CA186107, R01 CA151993, R35 CA197735, K07 CA190673, and P50 CA127003). Kentucky Case-Control Study was supported by the following grant support: Clinical Investigator Award from Damon Runyon Cancer Research Foundation (CI-8) and NCI R01CA136726. Melbourne Collaborative Cohort Study Axiom and OncoArray: Melbourne Collaborative Cohort Study cohort recruitment was funded by VicHealth and Cancer Council Victoria. The Melbourne Collaborative Cohort Study was further supported by Australian National Health and Medical Research Council grants 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. Multi-Ethnic Cohort Study: National Institutes of Health (R37 CA54281, P01 CA033619, and R01 CA63464). Molecular Epidemiology of Colorectal Cancer: This work was supported by the National Institutes of Health, US Department of Health and Human Services (R01 CA81488 to SBG and GR). Newfoundland Case-Control Study: This work was supported by an Interdisciplinary Health Research Team award from the Canadian Institutes of Health Research (CRT 43821); the National Institutes of Health, US Department of Health and Human Services (U01 CA74783); and National Cancer Institute of Canada grants (18223 and 18226). The authors wish to acknowledge the contribution of Alexandre Belisle and the genotyping team of the McGill University and G{\'e}nome Qu{\'e}bec Innovation Centre, Montr{\'e}al, Canada, for genotyping the Sequenom panel in the Newfoundland Case-Control Study samples. Funding was provided to Michael O. Woods by the Canadian Cancer Society Research Institute. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: Intramural Research Program of the Division of Cancer Epidemiology and Genetics was supported by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services. Additionally, a subset of control samples were genotyped as part of the Cancer Genetic Markers of Susceptibility Prostate Cancer Genome-Wide Association Study (Yeager et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645–649), Cancer Genetic Markers of Susceptibility pancreatic cancer scan (PanScan) (Amundadottir et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009;41:986–990, and Petersen et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010;42:224–228), and the Lung Cancer and Smoking study (Landi et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 2009;85:679–691). The prostate and PanScan study datasets were accessed with appropriate approval through the dbGaP online resource (http://cgems.cancer.gov/data/) accession numbers phs000207.v1.p1 and phs000206.v3.p2, respectively, and the lung datasets were accessed from the dbGaP website (http://www.ncbi.nlm.nih.gov/gap) through accession number phs000093.v2.p2. Funding for the Lung Cancer and Smoking study was provided by National Institutes of Health, Genes, Environment and Health Initiative Z01 CP 010200, National Institutes of Health U01 HG004446, and National Institutes of Health, Genes, Environment and Health Initiative U01 HG 004438. For the lung study, the GENEVA Coordinating Center provided assistance with genotype cleaning and general study coordination, and the Johns Hopkins University Center for Inherited Disease Research conducted genotyping. Vitamins and Lifestyle study was supported by National Institutes of Health (K05 CA154337). Women's Health Initiative program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. Genetics and Epidemiology of Colorectal Cancer Consortium: National Cancer Institute, National Institutes of Health, US Department of Health and Human Services (U01 CA137088; R01 CA059045; U01 CA164930). Funding Information: The American Cancer Society funds the creation, maintenance, and updating of the CPS2 cohort. The authors would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention{\textquoteright}s National Program of Cancer Registries, and cancer registries supported by the National Cancer Institute{\textquoteright}s Surveillance Epidemiology and End Results program. Publisher Copyright: {\textcopyright} 2018 AGA Institute",
year = "2018",
month = jun,
doi = "10.1053/j.gastro.2018.02.021",
language = "English (US)",
volume = "154",
pages = "2152--2164.e19",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "8",
}